Peer Advisor: Increasing HDL-cholesterol to Reduce Cardiovascular Risk: the Impact of Niacin Therapy

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
These multimedia CME activities are intended for cardiologists, primary care physicians, and healthcare practitioners who treat patients with lipid disorders.

1. Describe the safety and efficacy of niacin/simvastatin therapy in treating low HDL-cholesterol and elevated triglyceride levels
2. Identify and contrast pharmacologic agents used to treat lipid disorders
3. Discuss the clinical implications of cardiovascular residual risk

Accreditation:
These activities were reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by Mark A. Gendreau, MD, MS, Jennifer Verbesey, MD and Abigail Zavod, MD

Release Date: April 2008
Expiration Date: April 30, 2009

Millennium CME Institute, Inc., is accredited by the ACCME to provide continuing medical education for physicians. Millennium CME Institute, Inc., designates these CME-certified activities for a maximum total of 1.0 AMA PRA Category 1 Credits™. Participants should only claim credit commensurate with the extent of their participation in the activity.

© 2008 Millennium CME Institute, Inc. All rights reserved including translation into other languages. No part of this activity maybe reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Millennium CME Institute, Inc.

Faculty Disclosure:
Expert Commentary
James M. McKenney, PharmD, Professor Emeritus, Virginia Commonwealth University; President and CEO, National Clinical Research, Richmond, Virginia

Medical Reviewer
Mark A. Gendreau, MD, MS, Senior Staff Physician, Lahey Clinic, Burlington, Massachusetts

Planning Committee
Tim I. Robinson, President,
Millennium CME Institute, Inc., Hampton, New Hampshire

Frank A. Gesek, PhD, RPh, Clinical Affairs Specialist,
Millennium CME Institute, Inc., Hampton, New Hampshire

Peter B. Lindgren, PhD, Clinical Affairs Specialist,
Millennium CME Institute, Inc., Hampton, New Hampshire

Disclaimer
The opinions expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Abbott, any other manufacturer of pharmaceuticals, or Millennium CME Institute, Inc. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations
Millennium CME Institute, Inc., endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. All faculty are required to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations and with companies who have provided the commercial support for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no relationships to disclose:
Mark A. Gendreau, MD
Jennifer Verbesey, MD
Frank A. Gesek, PhD, RPh
Tim I. Robinson
Peter B. Lindgren, PhD
Abigail Zavod, MD

The faculty listed below have declared the following arrangements and/or affiliations:
James M. McKenney, PharmD: Speaker/Consultant: Astra Zeneca, Abbott, Aegerion, Merck & Co., Daiichi Sankyo

Signed disclosure forms are on file at Millennium CME Institute, Inc.

Off-label Usage Disclosure
This CME-certified activity does not contain information on commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Directions:
For each multimedia CME activity, the participant should read the learning objectives and review the content in its entirety. After reviewing the material, the participant should go to the CME Credit section to complete the Activity Self-assessment Test consiting of a series of multiple-choice questions.

Upon successfully completing each activity as designed and achieving a passing score of 70% or higher on the Activity Self-assessment Test, participants will receive a continuing education credit letter awarding the appropriate credit and the Activity Self-assessment Test answers four to six weeks after the receipt of the registration and evaluation materials.

Estimated time to complete these activities as designed is 4.0 hours.

CME Testing Options